首页 > 最新文献

European Journal of Nuclear Medicine and Molecular Imaging最新文献

英文 中文
The malignancy risk of thyroid incidentalomas detected by [18F]FDG PET/CT lower than expected: a nationwide observational study in the Netherlands. [18F]FDG PET/CT检测甲状腺偶发瘤的恶性风险低于预期:荷兰一项全国性观察性研究。
IF 7.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-08 DOI: 10.1007/s00259-025-07714-0
Hannelore I Coerts, Folkert J van Kemenade, Tessa M van Ginhoven, Menno R Vriens, M Medici, D Vriens, Bart de Keizer, Frederik A Verburg
{"title":"The malignancy risk of thyroid incidentalomas detected by [<sup>18</sup>F]FDG PET/CT lower than expected: a nationwide observational study in the Netherlands.","authors":"Hannelore I Coerts, Folkert J van Kemenade, Tessa M van Ginhoven, Menno R Vriens, M Medici, D Vriens, Bart de Keizer, Frederik A Verburg","doi":"10.1007/s00259-025-07714-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07714-0","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145916836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The integrated diagnostic strategy of performing PSMA PET/CT followed by MRI improves the diagnostic accuracy of prostate cancer PSMA PET/CT合并MRI的综合诊断策略提高了前列腺癌的诊断准确性
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-06 DOI: 10.1007/s00259-025-07731-z
Jiangyu Ma, Chu Wang, Miao Wang, Chao Ren, Zhenghai Huang, Yonghui Chen, Shuaitao Xiong, Jingxin Yang, Ming Liu, Li Huo
{"title":"The integrated diagnostic strategy of performing PSMA PET/CT followed by MRI improves the diagnostic accuracy of prostate cancer","authors":"Jiangyu Ma, Chu Wang, Miao Wang, Chao Ren, Zhenghai Huang, Yonghui Chen, Shuaitao Xiong, Jingxin Yang, Ming Liu, Li Huo","doi":"10.1007/s00259-025-07731-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07731-z","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"40 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-line [18F]F-choline PET/CT in primary hyperparathyroidism: a cost-effectiveness study from the diagnostic randomized APACH2 trial 一线f -胆碱PET/CT诊断原发性甲状旁腺功能亢进症[18F]:来自诊断性随机APACH2试验的成本-效果研究
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-06 DOI: 10.1007/s00259-025-07728-8
Elske Quak, Audrey Lasne-Cardon, Marie Cavarec, Franck Jegoux, Clémence Guery, Jean-Michel Grellard, Guy Thomas, Lawrence Nadin, Bénédicte Clarisse, Celia Berchi
{"title":"First-line [18F]F-choline PET/CT in primary hyperparathyroidism: a cost-effectiveness study from the diagnostic randomized APACH2 trial","authors":"Elske Quak, Audrey Lasne-Cardon, Marie Cavarec, Franck Jegoux, Clémence Guery, Jean-Michel Grellard, Guy Thomas, Lawrence Nadin, Bénédicte Clarisse, Celia Berchi","doi":"10.1007/s00259-025-07728-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07728-8","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"40 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Localization of an ectopic hepatic parathyroid adenoma with [18F]Flurpiridaz and [68Ga]Ga-FAPI: highlighting the complementary role of multimodality imaging [18F]氟吡达和[68Ga]Ga-FAPI在异位肝甲状旁腺瘤的定位:强调多模态成像的互补作用
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-06 DOI: 10.1007/s00259-025-07725-x
Kewei Zhou, Yulong Dou, Qifan Lian, Hao Song, Mengchun Li, Luyang Yang, Jing Liu, Sijin Li, Ping Wu
{"title":"Localization of an ectopic hepatic parathyroid adenoma with [18F]Flurpiridaz and [68Ga]Ga-FAPI: highlighting the complementary role of multimodality imaging","authors":"Kewei Zhou, Yulong Dou, Qifan Lian, Hao Song, Mengchun Li, Luyang Yang, Jing Liu, Sijin Li, Ping Wu","doi":"10.1007/s00259-025-07725-x","DOIUrl":"https://doi.org/10.1007/s00259-025-07725-x","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"40 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145902484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aortic valve calcium score from computed tomography for signal localization by cardiac amyloid radionuclide imaging to predict aortic stenosis and assess prognosis in patients with transthyretin cardiomyopathy. 经甲状腺素型心肌病患者主动脉瓣钙评分的计算机断层扫描信号定位与心脏淀粉样蛋白核素成像预测主动脉瓣狭窄和评估预后。
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-05 DOI: 10.1007/s00259-025-07718-w
Guillaume Bonnans,Philippe Blanc,Eve Cariou,Rémi Engel,Damien Legallois,Hugo Malerbi,Stéphanie Cazalbou,Yoan Lavie-Badie,Emmanuelle Cassol,Marie Beaurain,Pauline Fournier,Alain Manrique,Olivier Lairez,
{"title":"Aortic valve calcium score from computed tomography for signal localization by cardiac amyloid radionuclide imaging to predict aortic stenosis and assess prognosis in patients with transthyretin cardiomyopathy.","authors":"Guillaume Bonnans,Philippe Blanc,Eve Cariou,Rémi Engel,Damien Legallois,Hugo Malerbi,Stéphanie Cazalbou,Yoan Lavie-Badie,Emmanuelle Cassol,Marie Beaurain,Pauline Fournier,Alain Manrique,Olivier Lairez, ","doi":"10.1007/s00259-025-07718-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07718-w","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"24 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145897447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantitative dual-tracer PET/CT biomarkers correlate concordant lesion uptake with PSMA-RLT outcomes in mCRPC: a dual-center study. 定量双示踪PET/CT生物标志物与mCRPC中一致病变摄取与PSMA-RLT结果相关:一项双中心研究。
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-05 DOI: 10.1007/s00259-025-07700-6
Song Xue,Holger Einspieler,Sijie Wen,Dina Muin,Ana Antic Nikolic,Jan Baessler,Gero Kramer,Shahrokh F Shariat,Constantin Lapa,Marcus Hacker,Sazan Rasul,Xiang Li
{"title":"Quantitative dual-tracer PET/CT biomarkers correlate concordant lesion uptake with PSMA-RLT outcomes in mCRPC: a dual-center study.","authors":"Song Xue,Holger Einspieler,Sijie Wen,Dina Muin,Ana Antic Nikolic,Jan Baessler,Gero Kramer,Shahrokh F Shariat,Constantin Lapa,Marcus Hacker,Sazan Rasul,Xiang Li","doi":"10.1007/s00259-025-07700-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07700-6","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"29 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145897446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Total-body 11C-PIB PET/CT imaging of systemic amyloidosis: interorgan connectivity in cardiac amyloidosis for prognostic insights. 纠正:全身11C-PIB全身性淀粉样变性PET/CT成像:心脏淀粉样变性的器官间连通性对预后的启示。
IF 7.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-05 DOI: 10.1007/s00259-025-07730-0
Zhihui Hong, Song Xue, Josef Yu, Raffaella Calabretta, David Haberl, Zewen Jiang, Stefan Grünert, Dietrich Beitzke, Andreas Kammerlander, Marcus Hacker, Xiang Li
{"title":"Correction to: Total-body <sup>11</sup>C-PIB PET/CT imaging of systemic amyloidosis: interorgan connectivity in cardiac amyloidosis for prognostic insights.","authors":"Zhihui Hong, Song Xue, Josef Yu, Raffaella Calabretta, David Haberl, Zewen Jiang, Stefan Grünert, Dietrich Beitzke, Andreas Kammerlander, Marcus Hacker, Xiang Li","doi":"10.1007/s00259-025-07730-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07730-0","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145899711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative analysis of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT in advanced epithelial ovarian cancer: implications for preoperative scoring and treatment planning. 68Ga-FAPI-46 PET/CT与18F-FDG PET/CT在晚期上皮性卵巢癌中的对比分析:对术前评分及治疗计划的意义
IF 9.1 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-05 DOI: 10.1007/s00259-025-07721-1
Meihua Wu,Bing Hao,Zhengyi Chen,Tingting Xia,Haojun Chen,Qionghua Chen,Jianfa Lan
PURPOSETo evaluate the clinical impact of 18F-FDG PET/CT versus 68Ga-FAPI-46 PET/CT in patients with advanced epithelial ovarian cancer (EOC), this study aims to investigate preoperative scoring criteria and establish a basis for the formulation of treatment plans tailored to this patient population.METHODSA total of forty-one treatment-naive patients with advanced epithelial ovarian cancer were recruited for this study between July 2022 and February 2024. Each participant underwent both 18F-FDG and 68Ga-FAPI-46 PET/CT imaging. The study compared the diagnostic accuracy, PET/CT parameters, tumor staging, and the guidance provided for clinical treatment decisions by these two imaging modalities. Additionally, the tumor burden as assessed by both imaging techniques was evaluated to predict the likelihood of achieving R0 resection in subsequent surgical procedures.RESULTSIn the context of peritoneal metastasis, various PET/CT parameters were analyzed, including Gross Tumor Volume (GTV), SUVmax, Total Lesion Glycolysis (TLG(FDG)), and Total Lesion-FAPI (TL-FAPI). The comparative analysis of the two imaging modalities revealed statistically significant differences (P < 0.001). 68Ga-FAPI-46 PET/CT showed a higher PCI score and better sensitivity than 18F-FDG PET/CT (P = 0.03). Notably, the diagnostic accuracy of 68Ga-FAPI-46 PET/CT for detecting pelvic, para-aortic, and extra-abdominal lymph nodes was superior to that of 18F-FDG PET/CT, demonstrating enhanced sensitivity, specificity, and overall accuracy. Following the application of 68Ga-FAPI-46 PET/CT, tumor stages were upgraded in 22% (9 out of 41) of patients, while 39% (16 out of 41) exhibited alterations in their PET/CT scores relative to 18F-FDG PET/CT. Furthermore, the implementation of 68Ga-FAPI-46 PET/CT influenced treatment decisions in 17.1% (7 out of 41) of cases. For patients undergoing primary debulking surgery (PDS), receiver operating characteristic (ROC) curve analysis indicated that the GTV derived from both 18F-FDG PET/CT (AUC = 0.784, P = 0.018) and 68Ga-FAPI-46 PET/CT (AUC = 0.809, P = 0.010), along with TL-FAPI (AUC = 0.809, P = 0.010), demonstrated predictive value for incomplete resection during EOC debulking surgery.CONCLUSIONIn comparison to 18F-FDG, 68Ga-FAPI-46 PET/CT presents significant advantages in the detection of peritoneal and lymph node metastases, thereby providing a more accurate reference for the clinical staging of patients with advanced epithelial ovarian cancer. Importantly, 68Ga-FAPI-46 PET/CT has the potential to modify treatment decisions in nearly 20% of patients, facilitating the selection of more appropriate therapeutic strategies.
目的评价18F-FDG PET/CT与68Ga-FAPI-46 PET/CT对晚期上皮性卵巢癌(EOC)患者的临床影响,探讨术前评分标准,为制定适合该患者群体的治疗方案奠定基础。方法在2022年7月至2024年2月期间,共招募了41名未接受治疗的晚期上皮性卵巢癌患者。每位参与者都接受了18F-FDG和68Ga-FAPI-46 PET/CT成像。本研究比较了这两种成像方式的诊断准确性、PET/CT参数、肿瘤分期以及为临床治疗决策提供的指导。此外,对两种成像技术评估的肿瘤负荷进行了评估,以预测在后续手术中实现R0切除的可能性。结果在腹膜转移的背景下,我们分析了各种PET/CT参数,包括肿瘤体积(GTV)、SUVmax、总病变糖酵解(TLG(FDG))和总病变- fapi (TL-FAPI)。两种成像方式的比较分析显示差异有统计学意义(P < 0.001)。68Ga-FAPI-46 PET/CT的PCI评分高于18F-FDG PET/CT (P = 0.03)。值得注意的是,68Ga-FAPI-46 PET/CT对盆腔、主动脉旁淋巴结和腹外淋巴结的诊断准确性优于18F-FDG PET/CT,显示出更高的敏感性、特异性和总体准确性。应用68Ga-FAPI-46 PET/CT后,22%(9 / 41)患者的肿瘤分期升级,而39%(16 / 41)患者的PET/CT评分相对于18F-FDG PET/CT有改变。此外,68Ga-FAPI-46 PET/CT的实施影响了17.1%(41例中的7例)的治疗决策。对于接受原发性去肿块手术(PDS)的患者,受试者工作特征(ROC)曲线分析显示,18F-FDG PET/CT (AUC = 0.784, P = 0.018)和68Ga-FAPI-46 PET/CT (AUC = 0.809, P = 0.010)和TL-FAPI (AUC = 0.809, P = 0.010)得出的GTV对EOC去肿块手术中不完全切除具有预测价值。结论与18F-FDG相比,68Ga-FAPI-46 PET/CT在检测腹膜及淋巴结转移方面具有明显优势,可为晚期上皮性卵巢癌患者的临床分期提供更准确的参考。重要的是,68Ga-FAPI-46 PET/CT有可能改变近20%患者的治疗决策,促进选择更合适的治疗策略。
{"title":"Comparative analysis of 68Ga-FAPI-46 PET/CT and 18F-FDG PET/CT in advanced epithelial ovarian cancer: implications for preoperative scoring and treatment planning.","authors":"Meihua Wu,Bing Hao,Zhengyi Chen,Tingting Xia,Haojun Chen,Qionghua Chen,Jianfa Lan","doi":"10.1007/s00259-025-07721-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07721-1","url":null,"abstract":"PURPOSETo evaluate the clinical impact of 18F-FDG PET/CT versus 68Ga-FAPI-46 PET/CT in patients with advanced epithelial ovarian cancer (EOC), this study aims to investigate preoperative scoring criteria and establish a basis for the formulation of treatment plans tailored to this patient population.METHODSA total of forty-one treatment-naive patients with advanced epithelial ovarian cancer were recruited for this study between July 2022 and February 2024. Each participant underwent both 18F-FDG and 68Ga-FAPI-46 PET/CT imaging. The study compared the diagnostic accuracy, PET/CT parameters, tumor staging, and the guidance provided for clinical treatment decisions by these two imaging modalities. Additionally, the tumor burden as assessed by both imaging techniques was evaluated to predict the likelihood of achieving R0 resection in subsequent surgical procedures.RESULTSIn the context of peritoneal metastasis, various PET/CT parameters were analyzed, including Gross Tumor Volume (GTV), SUVmax, Total Lesion Glycolysis (TLG(FDG)), and Total Lesion-FAPI (TL-FAPI). The comparative analysis of the two imaging modalities revealed statistically significant differences (P < 0.001). 68Ga-FAPI-46 PET/CT showed a higher PCI score and better sensitivity than 18F-FDG PET/CT (P = 0.03). Notably, the diagnostic accuracy of 68Ga-FAPI-46 PET/CT for detecting pelvic, para-aortic, and extra-abdominal lymph nodes was superior to that of 18F-FDG PET/CT, demonstrating enhanced sensitivity, specificity, and overall accuracy. Following the application of 68Ga-FAPI-46 PET/CT, tumor stages were upgraded in 22% (9 out of 41) of patients, while 39% (16 out of 41) exhibited alterations in their PET/CT scores relative to 18F-FDG PET/CT. Furthermore, the implementation of 68Ga-FAPI-46 PET/CT influenced treatment decisions in 17.1% (7 out of 41) of cases. For patients undergoing primary debulking surgery (PDS), receiver operating characteristic (ROC) curve analysis indicated that the GTV derived from both 18F-FDG PET/CT (AUC = 0.784, P = 0.018) and 68Ga-FAPI-46 PET/CT (AUC = 0.809, P = 0.010), along with TL-FAPI (AUC = 0.809, P = 0.010), demonstrated predictive value for incomplete resection during EOC debulking surgery.CONCLUSIONIn comparison to 18F-FDG, 68Ga-FAPI-46 PET/CT presents significant advantages in the detection of peritoneal and lymph node metastases, thereby providing a more accurate reference for the clinical staging of patients with advanced epithelial ovarian cancer. Importantly, 68Ga-FAPI-46 PET/CT has the potential to modify treatment decisions in nearly 20% of patients, facilitating the selection of more appropriate therapeutic strategies.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"166 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145897597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis. 肽受体放射性核素治疗(PRRT)在高度神经内分泌肿瘤中的应用:一项系统综述和荟萃分析。
IF 7.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-03 DOI: 10.1007/s00259-025-07726-w
Emilia Zampella, Leandra Piscopo, Roberta Green, Valeria Cantoni, Carmela Nappi, Valeria Gaudieri, Elisa Caiazzo, Mariano Scaglione, Alberto Cuocolo, Michele Klain

Purpose: We performed a systematic review and meta-analysis to investigate the efficacy of peptide receptor radionuclide therapy (PRRT) by using radiolabeled somatostatin analogues in high grade gastro-entero-pancreatic neoplasms (GEP-NEN).

Methods: All clinical studies published up to March 2025, including patients with grade 3 (G3) GEP-NEN treated with [177Lu] Lu-DOTA-TATE and/or [90Y] Y-SSA, were identified based on systematic searches in the PubMed and Embase databases. Eligible studies had to report at least one of the following outcomes: 1) response to therapy evaluated according to RECIST (version 1.1 as complete response, partial response, stable disease, progressive disease; 2) median progression free survival (PFS) with 95% confidence intervals (CI); 3) median overall survival (OS) with 95% CI. Objective response rate (ORR) and disease control rate (DCR) were considered as primary outcomes.

Results: The final analysis included 7 studies accounting for a total of 317 patients with G3 disease (ranging from 18 to 112). Six studies evaluated response to therapy according to RECIST in 288 patients, and in 4 of them patients were also stratified according to ki67 values. The pooled ORR and DCR were 34% (95% CI: 22-46) and 64% (95% CI: 52-76), respectively. The funnel plot indicated no publication bias among these studies. Five studies reported in 239 patients median PFS with 95% CI, with a pooled estimate of 13.88 (95% CI: 10.33-18.64) months. Three studies fully reported in 174 patients median OS with 95% CI, with a pooled estimate of 29.95 (95% CI: 19.80-45.30) months.

Conclusions: In patients with G3 GEP-NEN, PRRT may provide substantial disease control and response rates, and it seems able to delay the progression of the disease.

目的:我们进行了一项系统回顾和荟萃分析,以研究使用放射性标记生长抑素类似物的肽受体放射性核素治疗(PRRT)在高级别胃-肠-胰腺肿瘤(GEP-NEN)中的疗效。方法:根据PubMed和Embase数据库的系统检索,确定截至2025年3月发表的所有临床研究,包括接受[177Lu] Lu-DOTA-TATE和/或[90Y] Y-SSA治疗的3级(G3) GEP-NEN患者。符合条件的研究必须报告以下至少一项结果:1)根据RECIST(版本1.1)评估的治疗反应(完全缓解、部分缓解、疾病稳定、疾病进展);2)95%置信区间(CI)的中位无进展生存期(PFS);3)中位总生存期(OS), 95% CI。客观缓解率(ORR)和疾病控制率(DCR)被认为是主要结局。结果:最终分析纳入7项研究,共317例G3病患者(18 ~ 112例)。6项研究根据RECIST评估288例患者对治疗的反应,其中4项研究也根据ki67值对患者进行分层。合并ORR和DCR分别为34% (95% CI: 22-46)和64% (95% CI: 52-76)。漏斗图显示这些研究没有发表偏倚。5项研究报告了239例患者的中位PFS, 95% CI,合并估计为13.88个月(95% CI: 10.33-18.64)。3项研究完全报道了174例患者的中位OS, 95% CI,合并估计为29.95个月(95% CI: 19.80-45.30)。结论:在G3 GEP-NEN患者中,PRRT可能提供实质性的疾病控制和缓解率,并且似乎能够延缓疾病的进展。
{"title":"Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis.","authors":"Emilia Zampella, Leandra Piscopo, Roberta Green, Valeria Cantoni, Carmela Nappi, Valeria Gaudieri, Elisa Caiazzo, Mariano Scaglione, Alberto Cuocolo, Michele Klain","doi":"10.1007/s00259-025-07726-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07726-w","url":null,"abstract":"<p><strong>Purpose: </strong>We performed a systematic review and meta-analysis to investigate the efficacy of peptide receptor radionuclide therapy (PRRT) by using radiolabeled somatostatin analogues in high grade gastro-entero-pancreatic neoplasms (GEP-NEN).</p><p><strong>Methods: </strong>All clinical studies published up to March 2025, including patients with grade 3 (G3) GEP-NEN treated with [<sup>177</sup>Lu] Lu-DOTA-TATE and/or [<sup>90</sup>Y] Y-SSA, were identified based on systematic searches in the PubMed and Embase databases. Eligible studies had to report at least one of the following outcomes: 1) response to therapy evaluated according to RECIST (version 1.1 as complete response, partial response, stable disease, progressive disease; 2) median progression free survival (PFS) with 95% confidence intervals (CI); 3) median overall survival (OS) with 95% CI. Objective response rate (ORR) and disease control rate (DCR) were considered as primary outcomes.</p><p><strong>Results: </strong>The final analysis included 7 studies accounting for a total of 317 patients with G3 disease (ranging from 18 to 112). Six studies evaluated response to therapy according to RECIST in 288 patients, and in 4 of them patients were also stratified according to ki67 values. The pooled ORR and DCR were 34% (95% CI: 22-46) and 64% (95% CI: 52-76), respectively. The funnel plot indicated no publication bias among these studies. Five studies reported in 239 patients median PFS with 95% CI, with a pooled estimate of 13.88 (95% CI: 10.33-18.64) months. Three studies fully reported in 174 patients median OS with 95% CI, with a pooled estimate of 29.95 (95% CI: 19.80-45.30) months.</p><p><strong>Conclusions: </strong>In patients with G3 GEP-NEN, PRRT may provide substantial disease control and response rates, and it seems able to delay the progression of the disease.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145891996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differential [18F]FAPI-42 and [18F]FDG uptake patterns distinguish desmoid tumours from GISTs on PET/CT imaging. 鉴别[18F]FAPI-42和[18F]FDG摄取模式在PET/CT成像上区分硬纤维瘤和gist。
IF 7.6 1区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2026-01-03 DOI: 10.1007/s00259-025-07707-z
Chunhui Wu, Xiaoyan Wang, Xiaojie Lin, Andor W J M Glaudemans, Bart Cornelissen, Walter Noordzij, Xin Hu, Yu Zeng, Xiangsong Zhang, Xinhua Zhang

Background: Intra-abdominal desmoid tumours (IADT) can closely mimic gastrointestinal stromal tumours (GISTs), particularly in recurrence and metastases. However, differentiating these two diseases using radiological methods remains challenging. This study aimed to investigate the value of [18F]FAPI-42 PET/CT in differentiating IADT and GISTs compared to [18F]FDG PET/CT.

Methods: This study retrospectively included a total of 24 patients (12 patients with IADT and 12 patients with recurrent/metastatic GISTs) who underwent two separate PET/CT scans using [18F]FAPI-42 and [18F]FDG, respectively. The differences in tumour SUVmax on [18F]FAPI-42 PET/CT (SUVmax-FAPI) and [18F]FDG PET/CT (SUVmax-FDG) and the ratio of tumour SUVmax on FAPI PET/CT to SUVmax on FDG PET/CT [SUVmax ratio (FAPI/FDG)] were compared between IADT and GISTs. Receiver operating characteristic (ROC) curve analyses were performed to evaluate the diagnostic performance of these parameters in differentiating IADTs from GISTs. Immunohistochemistry was used to verify FAP expression in all IADT lesions and GISTs lesions.

Results: The SUVmax of IADTs on [18F]FAPI-42 PET/CT was significantly higher than that of GISTs [8.8 (7.2, 10.6) vs. 3.9 (2.8, 7.6), P = 0.045], whereas the SUVmax of IADTs on [18F]FDG PET/CT was significantly lower than that of GISTs [2.5 (1.9, 3.5) vs. 6.1 (3.6, 8.3), P = 0.007]. The SUVmax ratio (FAPI/FDG) of IADTs was significantly higher than that of GISTs [3.3 (2.2, 4.1) vs. 0.8 (0.3, 1.4), P < 0.001]. SUVmax-FAPI, SUVmax-FDG, and the SUVmax ratio (FAPI/FDG) achieved AUCs of 0.743, 0.819, and 0.896, with corresponding accuracies of 75.0%, 83.3%, and 87.5%, respectively, for distinguishing IADT from GISTs. Immunohistochemistry revealed significantly higher FAP expression in IADTs compared to GISTs (P = 0.002), with most IADTs showing strong (3+) staining (8/12, 66.7%), while GISTs primarily demonstrated weak (1+) or no staining (7/12, 58.3%).

Conclusion: The distinct uptake characteristics of [18F]FAPI-42 and [18F]FDG observed in IADTs and GISTs provide preliminary evidence that these two tracers may offer complementary diagnostic information when evaluating desmoid tumours that mimic recurrent or metastatic GISTs.

背景:腹内硬纤维瘤(IADT)与胃肠道间质瘤(gist)非常相似,尤其是在复发和转移方面。然而,用放射学方法鉴别这两种疾病仍然具有挑战性。本研究旨在探讨[18F]FAPI-42 PET/CT与[18F]FDG PET/CT鉴别IADT和gist的价值。方法:本研究回顾性纳入24例患者(12例IADT患者和12例复发/转移性gist患者),分别使用[18F]FAPI-42和[18F]FDG进行两次单独的PET/CT扫描。比较[18F]FAPI-42 PET/CT上肿瘤SUVmax (SUVmax-FAPI)与[18F]FDG PET/CT上肿瘤SUVmax (SUVmax-FDG)的差异及FAPI PET/CT上肿瘤SUVmax与FDG PET/CT上肿瘤SUVmax的比值[SUVmax比值(FAPI/FDG)]。采用受试者工作特征(ROC)曲线分析来评估这些参数在区分iadt和gist中的诊断性能。免疫组化检测FAP在所有IADT病变和gist病变中的表达。结果:[18F]FAPI-42 PET/CT上IADTs的SUVmax明显高于gist组[8.8(7.2,10.6)比3.9 (2.8,7.6),P = 0.045],而[18F]FDG PET/CT上IADTs的SUVmax明显低于gist组[2.5(1.9,3.5)比6.1 (3.6,8.3),P = 0.007]。IADT的SUVmax比值(FAPI/FDG)显著高于gist [3.3 (2.2, 4.1) vs. 0.8 (0.3, 1.4)], P max-FAPI、SUVmax-FDG和SUVmax比值(FAPI/FDG)的auc分别为0.743、0.819和0.896,区分IADT与gist的准确率分别为75.0%、83.3%和87.5%。免疫组化显示FAP在IADTs中的表达明显高于gist (P = 0.002),大多数IADTs表现为强(3+)染色(8/12,66.7%),而gist主要表现为弱(1+)或无染色(7/12,58.3%)。结论:在IADTs和gist中观察到的[18F]FAPI-42和[18F]FDG的不同摄取特征提供了初步证据,表明这两种示踪剂可以在评估模拟复发或转移性gist的硬纤维瘤时提供互补的诊断信息。
{"title":"Differential [<sup>18</sup>F]FAPI-42 and [<sup>18</sup>F]FDG uptake patterns distinguish desmoid tumours from GISTs on PET/CT imaging.","authors":"Chunhui Wu, Xiaoyan Wang, Xiaojie Lin, Andor W J M Glaudemans, Bart Cornelissen, Walter Noordzij, Xin Hu, Yu Zeng, Xiangsong Zhang, Xinhua Zhang","doi":"10.1007/s00259-025-07707-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07707-z","url":null,"abstract":"<p><strong>Background: </strong>Intra-abdominal desmoid tumours (IADT) can closely mimic gastrointestinal stromal tumours (GISTs), particularly in recurrence and metastases. However, differentiating these two diseases using radiological methods remains challenging. This study aimed to investigate the value of [<sup>18</sup>F]FAPI-42 PET/CT in differentiating IADT and GISTs compared to [<sup>18</sup>F]FDG PET/CT.</p><p><strong>Methods: </strong>This study retrospectively included a total of 24 patients (12 patients with IADT and 12 patients with recurrent/metastatic GISTs) who underwent two separate PET/CT scans using [<sup>18</sup>F]FAPI-42 and [<sup>18</sup>F]FDG, respectively. The differences in tumour SUV<sub>max</sub> on [<sup>18</sup>F]FAPI-42 PET/CT (SUV<sub>max</sub>-FAPI) and [<sup>18</sup>F]FDG PET/CT (SUV<sub>max</sub>-FDG) and the ratio of tumour SUV<sub>max</sub> on FAPI PET/CT to SUV<sub>max</sub> on FDG PET/CT [SUV<sub>max</sub> ratio (FAPI/FDG)] were compared between IADT and GISTs. Receiver operating characteristic (ROC) curve analyses were performed to evaluate the diagnostic performance of these parameters in differentiating IADTs from GISTs. Immunohistochemistry was used to verify FAP expression in all IADT lesions and GISTs lesions.</p><p><strong>Results: </strong>The SUV<sub>max</sub> of IADTs on [<sup>18</sup>F]FAPI-42 PET/CT was significantly higher than that of GISTs [8.8 (7.2, 10.6) vs. 3.9 (2.8, 7.6), P = 0.045], whereas the SUV<sub>max</sub> of IADTs on [<sup>18</sup>F]FDG PET/CT was significantly lower than that of GISTs [2.5 (1.9, 3.5) vs. 6.1 (3.6, 8.3), P = 0.007]. The SUV<sub>max</sub> ratio (FAPI/FDG) of IADTs was significantly higher than that of GISTs [3.3 (2.2, 4.1) vs. 0.8 (0.3, 1.4), P < 0.001]. SUV<sub>max</sub>-FAPI, SUV<sub>max</sub>-FDG, and the SUV<sub>max</sub> ratio (FAPI/FDG) achieved AUCs of 0.743, 0.819, and 0.896, with corresponding accuracies of 75.0%, 83.3%, and 87.5%, respectively, for distinguishing IADT from GISTs. Immunohistochemistry revealed significantly higher FAP expression in IADTs compared to GISTs (P = 0.002), with most IADTs showing strong (3+) staining (8/12, 66.7%), while GISTs primarily demonstrated weak (1+) or no staining (7/12, 58.3%).</p><p><strong>Conclusion: </strong>The distinct uptake characteristics of [<sup>18</sup>F]FAPI-42 and [<sup>18</sup>F]FDG observed in IADTs and GISTs provide preliminary evidence that these two tracers may offer complementary diagnostic information when evaluating desmoid tumours that mimic recurrent or metastatic GISTs.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2026-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145892504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Journal of Nuclear Medicine and Molecular Imaging
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1